Provide ethical review services for clinical trials to ensure compliance with regulations. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Over the last 1 years, sales grew about 12% a year on average.
Sales run at $463.4M a year. A small number, but proof the product has real buyers.
A loss of $95.3M against $463.4M in annual sales.
At the current pace of spending, the cash lasts about 1.9 years. After that, the company needs to find new money.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the growth trend, earnings execution, the revenue breakdown, the price history.